New Scientist -- A drug that prevents immune rejection in human transplant patients has improved the memory of mice with a hereditary learning disorder. The finding suggests the disorder is a result of reversible abnormalities in brain chemistry rather than irreversible differences in architecture, as was previously assumed.
